C. Day

Epidemiology · Hepatology · 2007–2018

A researcher in the Science corpus: 14 papers; trusts 6 researchers and is trusted by 9 researchers here, as inferred from the citation graph.

Subfields

• Epidemiology — 233 citations into it; #359 of 2,148 by trust here, #134 by citations
• Endocrinology, Diabetes and Metabolism — 137 citations into it; #118 of 623 by trust here, #70 by citations
• Hepatology — 116 citations into it; #51 of 151 by trust here, #40 by citations
• Pathology and Forensic Medicine — 41 citations into it; #298 of 414 by trust here, #115 by citations

Whom C. Day trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. M. Talim
2. L. Adams
3. E. Bugianesi

Who trusts C. Day overall

1. V. Samuel
2. G. Targher
3. Christopher D. Byrne
4. Melania Gaggini

Papers from C. Day's perspective

Ordered by how strongly the researchers C. Day trusts endorse each paper. Same corpus, a different order for every researcher.

1. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study (Hepatology)
2. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity (Hepatology)
3. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome (Hepatology)
4. Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy (Annals of Internal Medicine)
5. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. (Journal of Clinical Endocrinology and Metabolism)
6. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference (Hepatology)
7. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis (New England Journal of Medicine)
8. NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States (Hepatology)
9. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis (Nature Reviews Gastroenterology &Hepatology)
10. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss (Hepatology)

Their papers

• Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease (2009) — 1,398 citations
• Cellular senescence drives age-dependent hepatic steatosis (2017) — 924 citations
• Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. (2018) — 1,677 citations
• Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis (2016) — 799 citations
• Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. (2015) — 1,003 citations
• TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease (2014) — 596 citations
• Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis (2013) — 1,661 citations
• Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease (2010) — 623 citations
• Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. (2010) — 1,751 citations
• A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010) — 1,090 citations
• HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin (2009) — 1,054 citations
• Non-alcoholic fatty liver disease: the mist gradually clears. (2008) — 613 citations
• The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD (2007) — 3,034 citations
• Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers (2007) — 760 citations